Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. from 2020 to 2030 and generate revenue of $151.7 The global chronic pain treatment market is predicted to progress at a CAGR of 6.5%

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

CannaMD

APRIL 23, 2020

In December of 2019, the company announced outstanding results in a pre-clinical mouse model of Parkinson’s disease. More specifically, they reported successfully using a cannabinoid-rich formula to get Parkinson’s-affected mice “back to baseline.” FDA in order to enter human clinical trial as early as this year!

Clinical Trials 116

Clinical Trials Research and Development Marijuana Treatment 116

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. SOURCE InMed Pharmaceuticals Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

MARCH 18, 2021

The study was compiled by way of an anonymous email survey sent to 7,607 people with Parkinson’s disease in January 2020. Any future research or clinical trials targeting the efficacy of cannabis should clearly define these recommendations for use and prioritize the communication of such recommendations to enrolled participants,” they added.

Patients 145

Patients Clinical Trials Treatment Cannabis 145

The Cannigma

MAY 19, 2021

This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 145

Law Legalization Clinical Trials CBD 145

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

Project CBD

FEBRUARY 28, 2023

This was somewhat less than the nearly 37% decline seen in 2020. sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. decline from 2020. COVID-19 plus legal uncertainty slowed CBD sales in 2020. million on these products. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. Following the execution of this work, cbdMD Therapeutics will perform the requisite toxicological studies with Ion Tox, a leading in vitro toxicology and ADME-PK testing company, to support the safety of the cannabinoids of interest. CHARLOTTE, N.C.–(BUSINESS

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

CannaMD

SEPTEMBER 9, 2020

Published only recently, in May of 2020, this clinical trial is the first to show that microdoses of cannabis can be just as effective as much higher doses. In fact, the very best dose of cannabis might be the dose you don’t immediately feel at all! Before getting into the study itself, though, let’s go over the basics.

Microdosing 111

Microdosing Marijuana Clinical Trials Chronic Pain 111

Cannabis Law Report

DECEMBER 23, 2021

This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. C3 Cannabinoid Compound Company. However, no single cannabinoid drug has received widespread approval in the treatment of pain. However, regulations are constantly shifting.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

CannaMD

NOVEMBER 15, 2020

research scene is also dominated by research on the harmful effects of cannabis, but Canada has dedicated much more funding to positive cannabinoid research. Non-profit organizations like the Canadian Consortium for Investigation of Cannabinoids (CCIC) were also formed to do research. In August 2020, the U.S.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

LifeCannMD

MAY 27, 2025

” His research, published in Cannabis and Cannabinoid Research , demonstrates that low doses of THC can actually produce opposite effects from high doses. Sleep: What the Sleep Studies Reveal A groundbreaking 2020 study from the University of New Mexico analyzed sleep data from over 5,000 medical marijuana patients.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

The Cannigma

AUGUST 14, 2022

There is certainly some evidence that cannabis may be helpful with increasing focus, in the right dose with the right terpenes and cannabinoids. The short answer is maybe – it depends on several factors, including the cannabinoids and terpenes in your weed, as well as how much you consume. It starts with the right cannabinoids.

Terpenes 128

Terpenes Strains THC Oil 128

Cannabis Law Report

JANUARY 27, 2022

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

Clinical Trials 40

Clinical Trials Therapy Cannabinoids Topical 40

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

LifeCannMD

AUGUST 2, 2024

Certain cannabinoids in marijuana, such as CBD, have anti-inflammatory properties. Cannabinoids like THC and CBD bind to ECS receptors, potentially reducing inflammation and pain perception. More clinical trials are needed to establish definitive efficacy and safety profiles. Migraines are often linked with inflammation.

Clinical Trials 52

Clinical Trials Marijuana Research and Development Cannabinoids 52

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

SpeedWeed

JULY 23, 2021

We’re interested in how cannabinoids affect the nervous system, the brain, and in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. Back in 2020, the company was granted the first Colorado cannabis research license to study dementia.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. 1.35, 95% CI [0.46–4.03]). 2.40, 95% CI [1.39–4.15]). Introduction.

Safety 52

Safety Cannabinoids Data Events 52

LifeCannMD

MAY 27, 2025

We’re looking at: Genetic testing to predict who’ll respond best to CBD Better combination strategies with traditional seizure meds New delivery methods for improved absorption Other cannabinoids that might help with seizures Just last month at a medical conference, researchers presented new findings about CBD’s mechanisms.

CBD 52

CBD Oil Epilepsy Sleep 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Puff Puff Post

JANUARY 1, 2020

Cannabinoids even alleviate certain types of pain that opiates don’t always treat well. Furthermore, cannabinoids treat these symptoms as the doctors either do chemotherapy or prescribe antivirals for the HIV. Approved Cannabinoid-Based Medications. National legalisation of medical cannabis could occur as early as 2020 in Spain.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.

Research and Development 124

Research and Development Data THC Clinical Trials 124

TheAnswerPage

MAY 29, 2021

A common adverse effect of chronic recreational marijuana use is cannabinoid hyperemesis syndrome. In fact, cannabinoid hyperemesis syndrome is a near daily diagnosis in many Canadian emergency departments. Anecdotal evidence supports the use of haloperidol to treat cannabinoid hyperemesis syndrome. mg/kg or 0.1 Ruberto, A.,

Clinical Trials 40

Clinical Trials Cannabinoids Treatment Recreational 40

The Cannigma

JUNE 24, 2021

In recent years, cannabis has been the subject of a tremendous amount of scientific research, and in 2020 there was a record number of scientific studies published on cannabis. Cannabinoids may ease nausea and vomiting. Isolated on their own, each of these cannabinoids and terpenes may have unique, therapeutic effects.

CBD 101

CBD Microdosing Edibles Sleep 101

The Cannigma

MARCH 15, 2021

In November, 2019, the Canadian tech company KEEP labs was named a CES 2020 Innovation Awards Honoree for their contribution to society — making a box that will allow dads to smoke weed at home without their kids finding it. Maybe, but the OTTO seems to have your best interests at heart. KEEP: The smart, safe cannabis storage box.

Concentrates 144

Concentrates Clinical Trials Chronic Pain Pets 144

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

MAY 10, 2022

The study, led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics , found anxiety was among the top three reasons for a medicinal cannabis prescription. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. fphar-13-885655.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

MARCH 22, 2020

Aurelius Data, a company dedicated to providing data around plant-based medicines, warned the public Tuesday that THC and COVID-19 don’t mix, based on what they know about how cannabinoids affect patients with influenza. 9:46 AM – Mar 19, 2020. Twitter Ads info and privacy. 7,739 people are talking about this.

THC 59

THC Clinical Trials Data Consumption 59

Veriheal

APRIL 18, 2022

A study by Yuval Zolotov and Staci Gruber from 2021 explains that “cannabis and cannabinoids may potentially alleviate a wide array of medical conditions that are prevalent among older adults including pain, arthritis, insomnia, anxiety and others.”.

Research and Development 98

Research and Development Clinical Trials Conditions Cannabis 98

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? It was also unique because it used whole-plant cannabis, rather than single-molecule extracts or synthetic pharmaceutical cannabinoids. .

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 16, 2019

On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Submissions are requested by 17 January 2020. Terms of Reference. n) any related matters.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Puff Puff Post

JANUARY 1, 2020

Cannabinoids even alleviate certain types of pain that opiates don’t always treat well. Furthermore, cannabinoids treat these symptoms as the doctors either do chemotherapy or prescribe antivirals for the HIV. Approved Cannabinoid-Based Medications. National legalisation of medical cannabis could occur as early as 2020 in Spain.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 40

Clinical Trials Research and Development Sleep Cannabinoids 40

CannaMD

AUGUST 26, 2020

A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.

Therapy 98

Therapy CBD Research and Development Treatment 98